Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.150
-0.020 (-1.71%)
Oct 8, 2026, 11:17 AM EDT - Market open
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $47.00M in the twelve months ending June 30, 2026, down -3.25% year-over-year. In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth. That makes Spero Therapeutics the 28,361st largest company in the world by revenue and 3,834th in the United States.
Revenue (ttm)
$47.00M
Revenue Growth
-3.25%
P/S Ratio
1.45
Revenue / Employee
$1,879,880
Employees
25
Market Cap
66.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| Champions Oncology | 60.66M |
| Gossamer Bio | 53.29M |
| Verrica Pharmaceuticals | 30.32M |
| iBio, Inc. | 100.00K |
SPRO News
- 2 days ago - Russian plague outbreak could boost these under-the-radar pharma stocks - Invezz
- 5 days ago - Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Spero Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 24 days ago - Spero Therapeutics price target raised to $6 from $5 at H.C. Wainwright - TheFly
- 4 weeks ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics files $300M mixed securities shelf - TheFly
- 5 weeks ago - Spero Therapeutics Registration statement: Registration filing - Filings